Results of Esbriet for Pulmonary Fibrosis published in NEJM - InterMune

InterMune has reported that results from the Phase III ASCEND study evaluating Esbriet (pirfenidone) in patients with Idiopathic Pulmonary Fibrosis (IPF) were presented at the International Conference of the American Thoracic Society (ATS) in San Diego, and published on-line in the New England Journal of Medicine. Talmadge King, Professor and Chair, Department of Medicine, University of California, San Francisco and Co-chair of the ASCEND protocol steering committee, presented the ASCEND results. The company intend to resubmit the pirfenidone New Drug Application to the FDA in the coming weeks. See: "A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis." Talmadge E. King et al. New England Journal of Medicine May 18, 2014 DOI: 10.1056/NEJMoa1402582